January 19, 2016
(Waltham, Mass; Feb. 19, 2016) — Executive thought leaders from Frenova Renal Research, the world’s only drug and medical device contract clinical development services provider dedicated exclusively to renal research, will discuss the future of clinical trials and ways to improve study success during sessions at the SCOPE Summit 2016, Feb. 23-25 in Miami.
Brigid Flanagan, senior director of clinical development at Frenova, will present “Partners in the Study Enterprise: Sponsor, CRO and Large Site Networks” at 3:35 p.m. EST Feb. 23. Vicki Duvall, director of global site management and clinical monitoring at Trevi Therapeutics, Inc., will co-present.
Flanagan will examine the case history of a study in which the sponsor invited both the CRO (clinical research organization) and the respective site networks to the kickoff meeting. “We’ll discuss how sponsors can involve key stakeholders early and how this can improve data quality, on-time deliverables and adherence to study budgets — all things critical to study success,” Flanagan said.
Bev Hudson, senior director of sales and marketing at Frenova, will moderate a roundtable discussion at Table 13 on “Clinical Trials in 2020: Where Are We Going?” with Hassan Kadhim, business consultant with Boehringer Ingelheim, at 4 p.m. EST Feb. 23.
Hudson’s forum will explore the role of the patient, the impact of technology and social media, and the global landscape of clinical trials for the years ahead.
“As professionals with years of experience on clinical studies, both Flanagan and Hudson have key insights to share to help sponsors make better decisions to improve their chances for success,” said Kurt Mussina, general manager at Frenova. “We welcome this opportunity to share our knowledge at these sessions, which we hope will lead to some thought-provoking discussions on these issues.”
Frenova’s experts in renal research programs will be available in Booth 203 to discuss current and upcoming projects. To schedule an appointment, email Russell.Smith@FrenovaRenalResearch.com.
For more information on Frenova’s renal research capabilities, visit the website at FrenovaRenalResearch.com.
About Frenova Renal Research
Frenova is the world’s only drug and medical device contract clinical development services provider dedicated exclusively to renal research. As a Fresenius Medical Care North America company, Frenova manages a networked system of clinical research assets and resources including more than 200 principal investigators and over 400 research experienced dialysis facilities. Frenova manages clinical trials in kidney and its adjacent disease areas and medical conditions. Frenova also offers clinical trial sponsors access to over 180,000 active dialysis dependent CKD patients and 400,000 active non-dialysis dependent CKD patients. For more information, visit www.FrenovaRenalResearch.com